Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of 芩香清解口服液 for acute upper respiratory tract infection
CTR20261892Phase 2Active
- Sponsor
- ApicHope Pharmaceutical Group
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Qinxiang Qingjie Oral Liquid in upper respiratory infection (URI), sponsored by ApicHope Pharmaceutical Group. Started May 2026; status: active.
02
Drugs
Qinxiang Qingjie Oral Liquid
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on CTR20261892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261892.